<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="356">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04402944</url>
  </required_header>
  <id_info>
    <org_study_id>P00035140</org_study_id>
    <nct_id>NCT04402944</nct_id>
  </id_info>
  <brief_title>Pulmozyme to Improve COVID-19 ARDS Outcomes</brief_title>
  <official_title>Pulmozyme to Improve COVID-19 ARDS Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized double-blind placebo-controlled Phase II trial of recombinant human
      deoxyribonuclease I (rhDNase I) - Pulmozyme - in mechanically ventilated patients with
      COVID-19 pneumonia.

      Patients admitted to the ICU with severe COVID-19 pneumonia who require mechanical
      ventilation will be invited to participate in this study. Potential subjects will be
      identified from medical record review or from direct contact with physicians. Investigators
      will check medical history and confirm eligibility. Informed consent will be obtained from
      either the patient or designated healthcare proxy.

      60 subjects will be enrolled. After obtaining informed consent, patients will be randomized
      2:1 to Pulmozyme 2.5 mg BID for up to 28 days or until they are no longer receiving
      mechanical ventilation, whichever is sooner plus standard of care vs. placebo normal saline
      2.5 ml plus standard of care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 18, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ventilator-free days at 28 days</measure>
    <time_frame>28 days</time_frame>
    <description>Primary outcome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in airway resistance</measure>
    <time_frame>28 days</time_frame>
    <description>change in airway resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in lung compliance</measure>
    <time_frame>28 days</time_frame>
    <description>Change in lung compliance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oxygenation (PaO2/FiO2 ratio)</measure>
    <time_frame>28 days</time_frame>
    <description>oxygenation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay (ICU and hospital)</measure>
    <time_frame>28 days</time_frame>
    <description>length of stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of barotrauma</measure>
    <time_frame>28 days</time_frame>
    <description>rate of batotrauma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality.</measure>
    <time_frame>28 days</time_frame>
    <description>mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID</condition>
  <arm_group>
    <arm_group_label>Study Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmozyme</intervention_name>
    <description>Pulmozyme 2.5 mg BID</description>
    <arm_group_label>Study Drug</arm_group_label>
    <other_name>Dornase alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline 2.5 mL BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ICU admission for pneumonia complicated by respiratory failure.

          -  RT-PCR (or equivalent) confirmed COVID-19 infection.

          -  Intubated and on mechanical ventilation within 48 hours of initiation of mechanical
             ventilation.

          -  Age ≥ 3 years of age.

        Exclusion Criteria:

          -  Allergy or known intolerance to Pulmozyme or Chinese Hamster Ovary cell products

          -  History of moderate to severe asthma, cystic fibrosis, or severe COPD (baseline FEV1 ≤
             40% predicted)

          -  Active malignancy other than basal cell melanoma or in situ breast cancer

          -  Unstable angina

          -  Chronic liver disease as judged by the investigator that would pose significant risk
             to participation

          -  Chronic renal disease as judged by the investigator that would pose significant risk
             to participation

          -  Patients unable to provide informed consent or who do not have a healthcare proxy to
             provide consent

          -  Patients are eligible for enrollment if they are already enrolled in another
             interventional study that does not involved inhaled medications

          -  Pregnant or breastfeeding

          -  Use of extracorporeal membrane oxygenation (ECMO)

          -  Prisoner status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Robert Fowler</last_name>
    <phone>6173551834</phone>
    <email>robert.fowler@childrens.harvard.edu</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Benjamiin Raby</investigator_full_name>
    <investigator_title>Chief of Respiratory Diseases</investigator_title>
  </responsible_party>
  <keyword>Pulmozyme</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>ARDS</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

